Literature DB >> 20406852

Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters.

Mirko Leonhardt1, Markus Keiser, Stefan Oswald, Jens Kühn, Jia Jia, Markus Grube, Heyo K Kroemer, Werner Siegmund, Werner Weitschies.   

Abstract

Contrast-enhancing magnetic resonance imaging with the liver-specific agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) has been shown to improve the detection rate of focal lesions. There is evidence from preclinical studies that multidrug organic anion transporters are involved in hepatic uptake of Gd-EOB-DTPA. Therefore, we evaluated affinity of the contrast agent to human organic anion-transporting polypeptides (OATP1B1, OATP1B3, OATP2B1) and to the Na(+)/taurocholate cotransporting polypeptide (NTCP) using stable transfected human embryonic kidney (HEK) 293 cells. In competition assays, Gd-EOB-DTPA inhibited the uptake of bromosulfophthalein (BSP) by OATP1B1 (IC(50) = 0.6 mM) and OATP1B3 (IC(50) = 0.4 mM). In comparison, the IC(50) values for rifampicin were 11.9 (OATP1B1), 1.4 (OATP1B3), and 80.5 muM (OATP2B1), respectively. Uptake of BSP by OATP2B1, uptake of taurocholic acid by NTCP, and viability of all HEK cells were not influenced by Gd-EOB-DTPA in concentrations up to 10 mM. In uptake assays using a new liquid chromatography-tandem mass spectrometry method for quantification, Gd-EOB-DTPA was a substrate for OATP1B1 (K(m) = 0.7 mM, V(max) = 10.5 pmol/mg x min), OATP1B3 (K(m) = 4.1 mM, V(max) = 22.7 pmol/mg x min), and NTCP (K(m) = 0.04 mM, V(max) = 1.4 pmol/mg x min). The uptake by OATP2B1 was not different from the vector control. In conclusion, Gd-EOB-DTPA is a substrate of the liver-specific OATP1B1, OATP1B3, and NTCP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406852     DOI: 10.1124/dmd.110.032862

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  90 in total

1.  Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study.

Authors:  Tatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2015-09-15       Impact factor: 7.527

2.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Authors:  Sith Phongkitkarun; Kuruwin Limsamutpetch; Penampai Tannaphai; Janjira Jatchavala
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

3.  Dual-modality gene reporter for in vivo imaging.

Authors:  P Stephen Patrick; Jayne Hammersley; Louiza Loizou; Mikko I Kettunen; Tiago B Rodrigues; De-En Hu; Sui-Seng Tee; Robin Hesketh; Scott K Lyons; Dmitry Soloviev; David Y Lewis; Silvio Aime; Sandra M Fulton; Kevin M Brindle
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-17       Impact factor: 11.205

4.  The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Akira Kunimatsu; Masanori Nojima; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

5.  Imaging techniques in the diagnosis of hepatocellular carcinoma and metastatic carcinoma as a result of colon cancer.

Authors:  Elmar M Merkle; Janio Szklaruk; Bachir Taouli
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

6.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

7.  Dynamic Contrast-Enhanced MRI of OATP Dysfunction in Diabetes.

Authors:  Dorela D Shuboni-Mulligan; Maciej Parys; Barbara Blanco-Fernandez; Christiane L Mallett; Regina Schnegelberger; Marilia Takada; Shatadru Chakravarty; Bruno Hagenbuch; Erik M Shapiro
Journal:  Diabetes       Date:  2018-11-28       Impact factor: 9.461

8.  Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage.

Authors:  Krishna Juluru; Andrew H Talal; Rhonda K Yantiss; Pascal Spincemaille; Elizabeth K Weidman; Ashley E Giambrone; Sadaf Jalili; Steven P Sourbron; Jonathan P Dyke
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

Review 9.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

10.  Diffusion kurtosis imaging in the assessment of liver function: Its potential as an effective predictor of liver function.

Authors:  Daisuke Yoshimaru; Yasuo Takatsu; Yuichi Suzuki; Toshiaki Miyati; Yuhki Hamada; Ayumu Funaki; Ayumi Tabata; Chifumi Maruyama; Masahiko Shimada; Maki Tobari; Takayoshi Nishino
Journal:  Br J Radiol       Date:  2018-11-01       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.